Udvalget for Humanmedicinske Lægemidler (CHMP) har konkluderet, at fordelene ved Fosavance er større end risiciene ved behandling af osteoporose hos postmenopausale patienter, som har risiko for D- vitaminmangel.
The Committee for Medicinal Products for Human Use (CHMP) decided that Fosavance’ s benefits are greater than its risks for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency.